Browse News
Filter News
Found 4,691 articles
-
OncoTracker CEO to Speak at 20th Annual SoCalBio Conference
9/24/2018
OncoTracker, Inc. announced that its Chief Executive Officer, James Kuo, MD, MBA, has been invited to speak at the 20th Annual SoCalBio Conference taking place on Friday, September 28, 2018
-
National Blood Cancer Experts Provide Updates on CAR T-Cell Therapy, Leukemia, Lymphoma, and Myeloma; New NCCN Guidelines for Systemic Mastocytosis Now Available
9/21/2018
The NCCN 13th Annual Congress: Hematologic Malignancies™ examines novel treatments, major milestones, and challenging case studies for hematologic oncology. Join the conversation online with the hashtag #NCCNhem18.
-
Molecular Templates and Takeda to Take on Multiple Myeloma in Deal Worth up to $632 Million
9/20/2018
Shares of Molecular Templates are up more than 52 percent in premarket trading after the company announced it has struck a deal with pharma giant Takeda Pharmaceuticals. -
Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease
9/20/2018
Management will be hosting one-on-one meetings at the conference
-
Targeted Oncology™ Launches its Latest Virtual Tumor Board on Multiple Myeloma
9/19/2018
Distinguished experts to provide in-depth insights on four patients with multiple myeloma
-
OncLive® Announces the Latest State of the Science Summit™ on the Treatment of Hematologic Malignancies
9/19/2018
Onclive the leading digital provider of resources and information to oncology professionals, will host the latest State of the Science Summit on treatment of hematologic malignancies.
-
Make Blood Cancer Visible: Janssen launches first-of-its-kind report to combat blood cancer myths in Asia Pacific
9/19/2018
New report highlights major gaps in understanding and significant misperceptions about blood cancer in the region, with one in two Japanese and one in four Chinese unable to name a single symptom of the disease
-
European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma
9/18/2018
Bristol-Myers Squibb Company today announced that the European Medicines Agency (EMA) has validated the Company’s type II variation application for Empliciti (elotuzumab) in combination with pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies
-
Actinium Pharmaceuticals to Host Webinar Showcasing New Pipeline Initiative Focused on the CAR-T Space
9/18/2018
Actinium Pharmaceuticals, Inc., (NYSE American: ATNM) ("Actinium" or "the Company"), announced today that it will unveil a new clinical initiative that expands the Company's pipeline into the CAR-T space.
-
Gamida Cell Strengthens Its Board of Directors with Appointment of Robert Blum as Chairman
9/18/2018
Julian Adams, Ph.D., Gamida Cell’s chief executive officer and previous chairman, will remain on the company’s board of directors.
-
As the Morgan Stanley Global Healthcare Conference runs from September 12 through 14, numerous biopharma companies are making presentations, updating their operations and pipeline activities. Here’s a look at some of the highlights.
-
Blood Cancer Survivor to Throw Out the First Pitch at Sept. 16 Houston Astros Game
9/13/2018
Event to Help Boost Multiple Myeloma Awareness and Planning
-
Immunotherapy Market Value Grows as the Treatments Gains Widespread Importance
9/13/2018
According to a report published by Progressive Markets, the cancer immunotherapy market was valued at USD 57.2 Billion in 2017 and is expected to reach USD 166.7 Billion by 2025 while growing at a compound annual growth (CAGR) of 14.42%.
-
OncLive® Presents the Latest State of the Science Summit™ on the Treatment of Hematologic Malignancies
9/13/2018
OncLive®, the leading digital provider of resources and information for oncology professionals, will host the latest State of the Science Summit™ on the treatment of hematologic malignancies Wednesday, September 19, from 5 to 9 p.m. at The Westin Seattle.
-
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Monotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Patients Whose Tumors Express PD-L1 (TPS ≥1%)
9/12/2018
Application Based on Overall Survival Data from Pivotal Phase 3 KEYNOTE-042 Trial
-
Burlington Stores and The Leukemia & Lymphoma Society Partner to Bring Smiles to Those Touched by Blood Cancers
9/12/2018
For 16 years, Burlington Stores has partnered with The Leukemia & Lymphoma Society (LLS), funding research and lifesaving treatments.
-
In May the U.S. Food and Drug Administration approved Amgen’s preventative migraine treatment Aimovig. Amgen and its developmental partner Novartis, said the medication would be ready within one week for patients.
-
Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label
9/11/2018
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has expanded the label for VENCLEXTA® (venetoclax tablets) in combination with rituximab to include information about patients with previously-treated chronic lymphocytic leukemia (CLL) who achieved minimal residual disease (MRD)-negativity in the Phase 3 MURANO trial.
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALK Genomic Tumor Aberrations
9/10/2018
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, in combination with pemetrexed (ALIMTA®) and platinum chemotherapy for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC) in adults whose tumors have no EGFR or ALK positive mutations.
-
RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma
9/10/2018
The first stage of the Phase IIa study with YELIVA® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can therefore continue to its second stage, enrolling the full cohort of 39 evaluable patients who previous received other treatments